[D2 根治术后辅助化疗对胃癌患者预后影响的Meta分析]

[Meta-analysis of adjuvant chemotherapy on prognosis for gastric cancer patients after D2 dissection].

作者信息

Xia Guang-gai, Zhang Chang-hua, Wei Zhe-wei, Wu Ying, He Yu-long

机构信息

Department of Gastrointestinopancreatic Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.

出版信息

Zhonghua Wai Ke Za Zhi. 2013 May 1;51(5):447-51.

PMID:23958170

Abstract

OBJECTIVE

To evaluate efficacy of adjuvant chemotherapy after D2 dissection on survival for patients with gastric cancer.

METHODS

Randomized clinical trials (RCT) that compared adjuvant chemotherapy after D2 dissection with D2 dissection alone for gastric cancer were searched with Pubmed, Cochrane, Embase and CBM databases. Eligible trials published between 1990 and 2012 were included in the study. The quality of RCTs was assessed by the Jadad scale. Data synthesis and statistical analysis were performed by RevMan 5.1 software.

RESULT

Eight RCTs with 3633 patients were included in this study. Among them, 1824 patients received adjuvant chemotherapy and 1809 patients didn't. Adjuvant chemotherapy was associated with a significant benefit in terms of overall survival (RR = 0.76, 95% CI: 0.69-0.84), disease free survival (RR = 0.72, 95%CI: 0.66-0.80) and recurrence rate (RR = 0.69, 95% CI: 0.62-0.77).

CONCLUSION

Adjuvant chemotherapy was associated with survival benefit for gastric cancer after D2 dissection.

摘要

目的

评估D2根治术后辅助化疗对胃癌患者生存的疗效。

方法

通过检索Pubmed、Cochrane、Embase和中国生物医学文献数据库（CBM），查找比较D2根治术后辅助化疗与单纯D2根治术治疗胃癌的随机临床试验（RCT）。纳入1990年至2012年发表的符合条件的试验。采用Jadad量表评估RCT的质量。使用RevMan 5.1软件进行数据合成和统计分析。

结果

本研究纳入了8项RCT，共3633例患者。其中，1824例患者接受了辅助化疗，1809例患者未接受。辅助化疗在总生存（RR = 0.76，95%CI：0.69 - 0.84）、无病生存（RR = 0.72，95%CI：0.66 - 0.80）和复发率（RR = 0.69，95%CI：0.62 - 0.77）方面具有显著益处。